BCR and chronic myelogenous leukemia, BCR-ABL1 positive: TKI impedes the ATP- tyrosine kinase binding and thereby halts the constitutive tyrosine kinase activity of the BCR-ABL1 oncoprotein and thus inhibits the CML progression.